Is MannKind Corp Finally a Buy?

MannKind Corporation (NASDAQ: MNKD) shares are up over 175% this month, and that's got anyone who's been paying attention to this troubled biotech wondering, "Can I still buy?" The company's massive short interest is likely behind a significant amount of the share-price rally, but the short covering was sparked by fundamental news regarding MannKind's inhalable insulin, Afrezza. So is this a stock investors should be buying?

MannKind's shares were trading below $1 as recently as August on the fear that a heavy debt load and anemic Afrezza sales would eventually result in the company's winding down.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com